BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...searches for a successor, Harry Welten will serve as interim CFO. He was CFO of Kuros...
BioCentury | Jun 15, 2017
Financial News

Checkmate raises $27M, names COO

...series A round from Sofinnova and venBio (see BioCentury, Aug. 17, 2015) . Chris Lieu CMP-001 Checkmate Pharmaceuticals Inc. Kuros...
BioCentury | Dec 16, 2016
Company News

Genocea, Checkmate deal

...Cytos Biotechnology AG . Kuros Biosurgery AG reverse-merged with Cytos Biotechnology AG in December 2015 to form Kuros...
BioCentury | Sep 5, 2016
Company News

Kuros Biosciences, Arbutus Biopharma deal

...Arbutus terminated a deal with Kuros, returning to Kuros worldwide rights to its virus-like particle (VLP...
...did not support further development. ARB-1598 is an agonist of toll-like receptor 9 (TLR9) . Kuros...
...that there are no financial terms associated with the termination (see BioCentury, Jan. 12, 2015). Kuros...
BioCentury | Jul 28, 2016
Targets & Mechanisms

Making sense of sensors

...the anti-PD-1 can work," Krieg said. Checkmate has the CpG DNA oligo CMP-001 partnered with Kuros...
...Inc. (NASDAQ:ADRO), Berkeley, Calif. Checkmate Pharmaceuticals Inc., Cambridge, Mass. Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. Kuros...
BioCentury | Jun 3, 2016
Financial News

LSP closes fifth fund at $280 million

...its capital to nine companies including immuno-oncology play Nouscom AG (Basel, Switzerland) and musculoskeletal company Kuros...
BioCentury | May 9, 2016
Finance

ven and now

...$52.0 Heart Metabolics Ltd. Repurposed generic drug perhexiline for hypertrophic cardiomyopathy 4/17/14 Series A $20.0 Kuros...
BioCentury | Dec 7, 2015
Finance

Eyes in Europe

...already made five investments from the fund, including investments in tissue repair and regeneration company Kuros Biosurgery AG...
BioCentury | Dec 7, 2015
Company News

Cytos, Kuros deal

...entity will be named Kuros Biosciences AG and focus on tissue repair and regeneration. Existing Kuros...
...shareholders will own about 80% of the company, and Cytos shareholders will hold the balance. Kuros’...
...IIb allergic asthma trial (see BioCentury, May 12, 2014). Cytos Biotechnology AG (SIX:CYTN), Schlieren, Switzerland Kuros Biosurgery AG...
BioCentury | Dec 4, 2015
Company News

Kuros reverse-merges with Cytos

...reverse merger with Cytos Biotechnology AG (SIX:CYTN). The combined entity will be Kuros Biosciences AG. Kuros'...
...will lead the merged company. Cytos Chairman and CEO Christian Itin will be chairman. Existing Kuros...
Items per page:
1 - 10 of 45
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...searches for a successor, Harry Welten will serve as interim CFO. He was CFO of Kuros...
BioCentury | Jun 15, 2017
Financial News

Checkmate raises $27M, names COO

...series A round from Sofinnova and venBio (see BioCentury, Aug. 17, 2015) . Chris Lieu CMP-001 Checkmate Pharmaceuticals Inc. Kuros...
BioCentury | Dec 16, 2016
Company News

Genocea, Checkmate deal

...Cytos Biotechnology AG . Kuros Biosurgery AG reverse-merged with Cytos Biotechnology AG in December 2015 to form Kuros...
BioCentury | Sep 5, 2016
Company News

Kuros Biosciences, Arbutus Biopharma deal

...Arbutus terminated a deal with Kuros, returning to Kuros worldwide rights to its virus-like particle (VLP...
...did not support further development. ARB-1598 is an agonist of toll-like receptor 9 (TLR9) . Kuros...
...that there are no financial terms associated with the termination (see BioCentury, Jan. 12, 2015). Kuros...
BioCentury | Jul 28, 2016
Targets & Mechanisms

Making sense of sensors

...the anti-PD-1 can work," Krieg said. Checkmate has the CpG DNA oligo CMP-001 partnered with Kuros...
...Inc. (NASDAQ:ADRO), Berkeley, Calif. Checkmate Pharmaceuticals Inc., Cambridge, Mass. Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. Kuros...
BioCentury | Jun 3, 2016
Financial News

LSP closes fifth fund at $280 million

...its capital to nine companies including immuno-oncology play Nouscom AG (Basel, Switzerland) and musculoskeletal company Kuros...
BioCentury | May 9, 2016
Finance

ven and now

...$52.0 Heart Metabolics Ltd. Repurposed generic drug perhexiline for hypertrophic cardiomyopathy 4/17/14 Series A $20.0 Kuros...
BioCentury | Dec 7, 2015
Finance

Eyes in Europe

...already made five investments from the fund, including investments in tissue repair and regeneration company Kuros Biosurgery AG...
BioCentury | Dec 7, 2015
Company News

Cytos, Kuros deal

...entity will be named Kuros Biosciences AG and focus on tissue repair and regeneration. Existing Kuros...
...shareholders will own about 80% of the company, and Cytos shareholders will hold the balance. Kuros’...
...IIb allergic asthma trial (see BioCentury, May 12, 2014). Cytos Biotechnology AG (SIX:CYTN), Schlieren, Switzerland Kuros Biosurgery AG...
BioCentury | Dec 4, 2015
Company News

Kuros reverse-merges with Cytos

...reverse merger with Cytos Biotechnology AG (SIX:CYTN). The combined entity will be Kuros Biosciences AG. Kuros'...
...will lead the merged company. Cytos Chairman and CEO Christian Itin will be chairman. Existing Kuros...
Items per page:
1 - 10 of 45